RPG Life Sciences LimitedRPGLIFECorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data

₹2,940.60

MCap ₹4,863 Cr · P/E 40.6

RPG Life Sciences Limited — Stock analysis & AI research RPG Life Sciences Limited — Multibagger AI analysis RPG Life Sciences Limited — Seasonality — best & worst months RPG Life Sciences Limited — Technical indicators & charts RPG Life Sciences Limited — Technical setup — score, trend, support & resistance RPG Life Sciences Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Interest Coverage Stocks 📋 Low Debt Stocks 📋 High Promoter Holding Stocks 📋 Quality + Momentum Stocks 📈 Bullish EMA Alignment 📈 Volume Dry-Up Stocks 📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹196 Cr

Sales · Jun 2026

+15.8% YoY

₹44 Cr

Operating Profit · Jun 2026

+22.9% YoY

22.3%

OPM % · Jun 2026

+6.2% YoY

₹31 Cr

Net Profit · Jun 2026

+16.3% YoY

₹18.49

EPS · Jun 2026

+16.3% YoY

📝 RPG Life Sciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

RPG Life Sciences Limited reported revenue of ₹196 crore for the quarter ended June 2026 (Q1 FY27), up 15.8% from ₹169 crore in the same quarter last year, and up 10.6% sequentially over the March 2026 quarter.

Net profit rose 16.3% year-on-year to ₹31 crore, from ₹26 crore. Earnings per share (EPS) came in at ₹18.49.

Operating profit stood at ₹44 crore — an operating margin (OPM) of 22.3%, compared with 21.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, RPG Life Sciences Limited posted revenue of ₹708 crore, a growth of 8.4% over FY25, with a net profit of ₹115 crore (down 36.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹735 crore with a net profit of ₹120 crore.

Valuation snapshot

At the current price of ₹2,940.60, RPGLIFE has a market capitalisation of ₹4,863 crore and a trailing P/E of about 40.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 12th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.95%, foreign institutional investors (FIIs) 0.87%, domestic institutional investors (DIIs) 9.93%, public shareholders 16.25% of RPG Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹4,863 Cr

Current Price ?

₹2,940.6

P/E ?

40.63above ind

Industry P/E ?

37.20

P/B ?

8.04

P/S ?

6.62

P/FCF ?

N/A

Enterprise Value ?

₹4,883 Cr

EV/EBITDA ?

31.44

PEG ?

2.26

Earnings Yield ?

2.7%

Dividend Yield ?

0.68%

Profitability & Returns

Sales (TTM) ?

₹735 Cr

OPM ?

21.1%

Profit after tax (TTM) ?

₹120 Cr

EPS (TTM) ?

₹72.37

ROCE ?

26.0%

ROE ?

19.8%

ROA ?

15.1%

Growth

Sales — latest qtr ?

₹196 Cr

PAT — latest qtr ?

₹31 Cr

YoY qtr sales growth ?

15.8%

YoY qtr profit growth ?

16.3%

Sales growth (3y) ?

11%

Sales growth (5y) ?

13%

Profit growth (3y) ?

18%

Profit growth (5y) ?

23%

Financial Health

Debt ?

₹20 Cr

Debt to Equity ?

0.03

Interest Coverage ?

330.8

Current Ratio ?

N/A

Ownership

Promoter holding ?

72.95%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

2.8%

Return 6 months ?

45.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	118	148	154	154	127	165	172	173	143	169	182	180	177	196	+15.8%	+10.6%
Operating Profit	16	32	37	38	21	39	46	49	25	35	39	40	33	44	+22.9%	+32.1%
Other Income	2	2	2	2	2	2	-25	3	115	5	16	3	13	4	-20.5%	-68.0%
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	1	+384.6%	—
Depreciation	4	4	4	4	4	5	5	5	5	5	5	5	6	6	+14.8%	-1.7%
Profit Before Tax	14	30	35	36	18	36	15	47	135	35	49	29	40	41	+16.3%	+3.0%
Net Profit	10	22	26	26	13	27	4	35	117	26	37	22	30	31	+16.3%	+1.9%
EPS	6.26	13.36	15.64	16.00	8.01	16.18	2.54	21.12	70.95	15.90	22.28	13.38	18.08	18.49	+16.3%	+2.3%
OPM %	13.6%	21.6%	24.0%	24.7%	16.5%	23.6%	26.7%	28.3%	17.5%	21.0%	21.4%	22.1%	18.6%	22.3%	+6.2%	+19.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹653 Cr	₹708 Cr	₹735 Cr	+8.4%
Operating Profit	₹159 Cr	₹147 Cr	₹155 Cr	-7.4%
OPM %	24.35%	20.80%	21.14%	-14.6%
NPM %	28.02%	16.30%	16.29%	-41.8%
Other Income	₹95 Cr	₹38 Cr	₹37 Cr	-60.4%
Depreciation	₹20 Cr	₹22 Cr	₹22 Cr	+7.6%
Interest	₹0 Cr	₹0 Cr	₹1 Cr	—
EBIT	₹139 Cr	₹126 Cr	₹133 Cr	-9.6%
PBT	₹233 Cr	₹154 Cr	₹159 Cr	-34.1%
Tax	—	₹16 Cr	₹18 Cr	—
Net Profit	₹183 Cr	₹115 Cr	₹120 Cr	-36.9%
EPS	₹110.79	₹69.64	₹72.23	-37.1%
Material Cost	—	₹144 Cr	₹156 Cr	—
Employee Cost	—	₹69 Cr	₹73 Cr	—
Extraordinary Items	—	₹-8 Cr	₹-8 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	13	13	13	13	+0.0%
Reserves	294	362	517	592	+14.5%
Borrowings	0	0	0	20	—
Other Liabilities	112	138	127	168	+32.3%
Total Liabilities	419	513	658	793	+20.5%
Fixed Assets	124	114	172	200	+16.3%
CWIP	25	96	16	20	+25.0%
Investments	58	91	127	120	-5.5%
Other Assets	211	212	343	454	+32.4%
Total Assets	419	513	658	793	+20.5%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	91	94	78	0	-100.0%
Cash from Investing Activity	-106	-79	-42	0	+100.0%
Cash from Financing Activity	-17	-20	-27	0	+100.0%
Net Cash Flow	-32	-5	9	0	-100.0%
Free Cash Flow	58	25	151	0	-100.0%
CFO/OP	111%	96%	81%	0%	-100.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	27	31	48	60	+25.0%
Inventory Days	203	200	159	179	+12.6%
Days Payable	138	140	135	141	+4.4%
Cash Conversion Cycle	91	90	72	99	+37.5%
Working Capital Days	33	25	45	107	+137.8%
ROCE %	33%	35%	33%	26%	-21.2%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	72.95%	72.95%	72.95%	72.95%	72.95%	72.95%	+0.0%
FIIs	1.35%	1.11%	1.00%	0.87%	0.95%	0.87%	-8.4%
DIIs	6.49%	6.70%	7.04%	7.45%	8.67%	9.93%	+14.5%
Public	19.22%	19.23%	19.01%	18.72%	17.42%	16.25%	-6.7%
No. of Shareholders	25,832	26,657	25,905	25,282	23,886	24,330	+1.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	KOPRAN Kopran	₹281.55	1,361	54.5	700	25	8.7%	3.6%	-96.0%	-97.6%	13.9%	-10.0%

❓ Frequently asked questions

What was RPG Life Sciences Limited's revenue in Q1 FY27?

What was RPG Life Sciences Limited's net profit in Q1 FY27?